Fig. 4From: Imaging biomarkers for evaluating tumor response: RECIST and beyondTumor necrosis indicates early good response in non-small cell lung cancer (NSCLC) receiving targeted therapy. A 53-year-old man diagnosed with NSCLC (positive EGFR exon 20 insertion mutations) and received afatinib therapy. AÂ Pretreatment contrast-enhanced (CE) axial CT scan shows an enhancing tumor (arrow), with diameter of 64 mm. B, CÂ Pseudo-progression with increased tumor size (arrow) was observed in 3 months (B) (67 mm in tumor diameter) and 8 months (C) (74 mm in tumor diameter) after targeted therapy. Simultaneously, the progression of focal tumor necrosis (arrowheads in figure B) to diffuse tumor necrosis (C) was also observed. DÂ Shrinkage of tumor mass (50 mm in diameter) was observed 15 months after therapyBack to article page